We show here that a significant skewing of T cell activation towards TH17 functional phenotype exists in COVID-19 patients, and we therefore suggest that blocking IL-17 pathway by biological drugs that are already available and used to treat different pathologies could be a novel, additional strategy to treat patients infected by SARS-CoV-2. This evidence concerns the gene IL17A and COVID-19.